This move diversifies options for patients following the earlier approval of Eisai and Biogen's Leqembi in January. CVS faces ...

(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Shares of Biogen Inc. BIIB inched 0.10% higher to $150.64 Tuesday, on what proved to be an all-around grim trading session ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Stifel Nicolaus lowered shares of Biogen (NASDAQ:BIIB – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday, MarketBeat.com reports. Stifel Nicolaus ...

ADNOC Drilling , a unit of the United Arab Emirates' state oil giant, said on Tuesday it has closed an agreement to create ...

Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...

Stifel analyst Paul Matteis downgraded Biogen (BIIB) to Hold from Buy with a $175 price target It’s been a challenging year and while there are other reasons that are contributing, it’s “mostly driven ...